IN8bio (INAB) announced the promotion of Kate Rochlin, Ph.D., to President and COO, effective immediately. Dr. Rochlin has served as IN8bio’s COO since December 2021, following her tenure as Vice President and Associate Vice President of Operations and Innovation beginning in August 2020. In her expanded role, she will continue to oversee company operations as IN8bio advances its clinical and preclinical pipeline and prepares for its next phase of growth.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INAB:
- IN8bio files to sell 14.38M shares of common stock for holders
- IN8bio: Clinical Momentum, Strengthened Cash Runway, and Unmodeled Pipeline Upside Support Buy Rating
- IN8bio presents Phase I/II data from INB-200 trials
- IN8bio Announces Structured $40 Million Private Placement Financing
- IN8bio prices 5.13M shares at $1.38 in private placement